Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Limited has announced a proposed capital raising via a placement and related securities issue, seeking to issue up to 690,099,278 new fully paid ordinary shares, 4,000,000 convertible notes, and a substantial number of options expiring in 2029 and 2030. The transaction, slated for completion around 11 March 2026, would significantly expand the company’s capital base and provide additional funding flexibility, potentially diluting existing shareholders but strengthening its financial position to support ongoing operations and future growth initiatives.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an Australian-listed biotechnology company focused on developing innovative therapeutic products, with its ordinary shares traded on the ASX under the code CHM. It operates in the life sciences sector, using capital markets funding to support the advancement of its clinical and research pipeline.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
For an in-depth examination of CHM stock, go to TipRanks’ Overview page.